Company Overview - Envista (NVST) is expected to report a year-over-year decline in earnings, with a projected EPS of $0.23, reflecting a decrease of -20.7% compared to the previous year [3] - Revenue for the upcoming quarter is anticipated to be $646.15 million, which represents a slight increase of 0.1% from the same quarter last year [3] Earnings Expectations - The consensus EPS estimate has been revised down by 0.57% over the last 30 days, indicating a reassessment by analysts [4] - The Most Accurate Estimate for Envista is higher than the Zacks Consensus Estimate, resulting in a positive Earnings ESP of +2.22%, suggesting a likelihood of beating the consensus EPS estimate [10][11] Historical Performance - In the last reported quarter, Envista exceeded the expected EPS of $0.09 by delivering $0.12, resulting in a surprise of +33.33% [12] - Over the past four quarters, Envista has only beaten consensus EPS estimates once [13] Market Sentiment - The upcoming earnings report is set to be released on February 5, and the stock may experience upward movement if the results exceed expectations, while a miss could lead to a decline [2] - The company's current Zacks Rank is 3, indicating a hold position, which suggests a moderate outlook for the stock [11] Industry Context - In comparison, BellRing Brands (BRBR), another player in the Zacks Medical - Products industry, is expected to post earnings of $0.47 per share, reflecting a year-over-year increase of +9.3% [17] - BellRing Brands has an Earnings ESP of 2.15% but carries a Zacks Rank of 4 (Sell), making it difficult to predict a beat on the consensus EPS estimate [18]

Earnings Announcement and Conference Call Details - Envista Holdings Corporation will report its Q4 2024 financial results on February 5, 2025, with the conference call scheduled to begin at 2:30 PM PT [1] - The conference call will last approximately one hour and will be accompanied by a slide presentation [1] - The webcast of the call and presentation will be available on the "Investors" section of Envista's website, with a replay accessible for one year [2] - Participants can access the conference call by dialing 800-225-9448 (U S) or +1 203-518-9708 (international) using conference ID 7185081 [2] - Earnings press release, webcast slides, and related materials will be posted on the "Investors" section of Envista's website before the call and remain available afterward [3] Company Overview - Envista Holdings Corporation is a global dental products company with over 30 trusted brands, including Nobel Biocare, Ormco, DEXIS, and Kerr [4] - The company focuses on partnering with dental professionals to improve patient care through dental consumables, solutions, technology, and services [4] - Envista's product portfolio includes dental implants, orthodontics, digital imaging technologies, and treatment options, addressing a wide range of clinical needs [4] - The company operates with the Envista Business System (EBS) methodology, emphasizing continuous improvement, innovation, and customer focus [4] - Envista holds significant market positions in attractive segments of the dental products industry and is one of the largest global dental products companies [4] Investor Relations Contact - James Gustafson, Vice President of Investor Relations, is the primary contact for further information regarding Envista Holdings Corporation [5] - The company's headquarters is located at 200 S Kraemer Blvd, Building E, Brea, CA 92821, with a contact number of (714) 817-7000 [5]

Group 1 - The article focuses on the Asia Value & Moat Stocks research service, which targets value investors looking for Asia-listed stocks with significant discrepancies between price and intrinsic value [1] - The service emphasizes deep value balance sheet bargains, such as net cash stocks and low price-to-book (P/B) stocks, as well as wide moat stocks that represent high-quality businesses [1] - The author provides a range of watch lists with monthly updates, particularly concentrating on investment opportunities in the Hong Kong market [1]

Earnings Announcement and Conference Call - Envista Holdings Corporation will report its Q4 2024 financial results on February 5, 2025, with a conference call scheduled for the same day at 2:00 PM PT, lasting approximately one hour [1] - The conference call and accompanying slide presentation will be webcast on the "Investors" section of Envista's website, with a replay available shortly after the conclusion and accessible for one year [2] - Participants can access the conference call by dialing 800-225-9448 within the U S or +1 203-518-9708 outside the U S, using conference ID 7185081 [2] - Envista's earnings press release, webcast slides, and related materials will be posted on the "Investors" section of the company's website before the call and remain available afterward [3] Company Overview - Envista is a global dental products company with over 30 trusted brands, including Nobel Biocare, Ormco, DEXIS, and Kerr, focused on improving lives through partnerships with dental professionals [4] - The company offers a comprehensive portfolio of dental consumables, solutions, technology, and services, covering dental implants, orthodontics, digital imaging, and aesthetic solutions [4] - Envista operates with the Envista Business System (EBS) methodology, supported by an experienced leadership team and a culture of continuous improvement, innovation, and customer focus [4] - As one of the largest global dental products companies, Envista holds significant market positions in attractive segments of the dental industry [4]

Company Overview - Envista Holdings Corporation is a global leader in the dental products industry, with a portfolio of over 30 trusted dental brands including Nobel Biocare, Ormco, DEXIS, and Kerr [2] - The company focuses on partnering with dental professionals to improve patient care through innovative dental consumables, solutions, technology, and services [2] - Envista's comprehensive product portfolio includes dental implants, orthodontics, and digital imaging technologies, addressing a wide range of clinical needs for diagnosing, treating, and preventing dental conditions [2] - The company operates with the Envista Business System (EBS) methodology, emphasizing continuous improvement, innovation, and customer focus [2] - Envista holds significant market positions in some of the most attractive segments of the dental products industry [2] Upcoming Event - Envista will participate in a presentation at the 43rd Annual J P Morgan Healthcare Conference on January 15, 2025, from 9:45 – 10:25 am PT at the Westin St Francis Hotel in San Francisco [1] - An audio-only recording of the presentation will be available on Envista's Investor Relations website for up to 30 days following the event [1]

Envista Holdings Corporation’s (NVST) rise in the third quarter of 2024 is backed by robust growth within the Specialty Products and Technologies business. Strategic acquisition deals look promising for growth. Meanwhile, a debt-burdened balance sheet and dull macroeconomic environment remain concerns for NVST’s operations.  In the past year, this Zacks Rank #3 (Hold) company’s shares have lost 8.8% against 17.3% growth of the industry. The S&P 500 composite rose 30.8% during the same time frame.The leading ...

BREA, Calif., Nov. 20, 2024 /PRNewswire/ -- Envista Holdings Corporation (NYSE: NVST) today announced the release of its 2023 Sustainability Report, outlining its continued efforts to integrate environmental, social, and governance (ESG) considerations into its mission to digitize, personalize, and democratize dental care. The full report can be found HERE."Our efforts to promote improved environment, social, and governance initiatives are central to how we support our stakeholders. Through the lens of our ...

BREA, Calif., Nov. 19, 2024 /PRNewswire/ -- Envista Holdings Corporation (NYSE: NVST) ("Envista") today announced that the company will participate in a fireside chat at the Evercore HealthCONx Conference on Tuesday, December 3, 2024 from 12:30 – 1:15 pm ET at the Loews Coral Gables Hotel in Coral Gables, Florida. There will be an audio-only recording link that can be viewed on Envista's Investor Relations website for up to 365 days post event.ABOUT ENVISTA HOLDINGS CORPORATIONEnvista is a global family of ...

Financial Data and Key Metrics Changes - Reported sales for Q3 2024 were $601 million, with core sales declining 5.3% year-over-year after adjusting for currency exchange rates [17] - Adjusted gross margin was 52.8%, down 490 basis points compared to the prior year [23] - Adjusted EBITDA margin for the quarter was 9.1%, which is 10.5 percentage points lower than the previous year [23] - Adjusted diluted EPS in Q3 was $0.12, compared to $0.43 in Q3 2023 [23] - Free cash flow for the quarter was $63 million, down from $77 million in Q3 of the previous year, but year-to-date free cash flow was $179 million, up 45% year-over-year [37] Business Line Data and Key Metrics Changes - Specialty products and technology segment saw a core revenue decline of 5.2% year-over-year, with orthodontic business declining low double digits due to Spark revenue deferral impact [30] - Implant growth was flat year-over-year, with North America showing improvement as the gap relative to market continued to close [32] - Equipment and consumables segment core sales decreased by 5.6% year-over-year, with diagnostics business declining mid-single digits, although North America grew for the third consecutive quarter [34] Market Data and Key Metrics Changes - North America business declined mid-single digits, while West Europe declined high single digits [21] - China business declined low double digits, primarily due to weaker diagnostic sales [22] - The overall dental market was generally flat, with some segments like implants showing slight growth [12] Company Strategy and Development Direction - The company reaffirmed its full-year guidance of negative 1% to negative 4% core growth and 10% to 12% adjusted EBITDA margins, expecting a return to growth in Q4 [39] - Focus on rebuilding operational capabilities and improving execution rhythm, with significant investments in leadership and the Envista Business System [41] - Continued commitment to innovation and customer engagement, with various events held to strengthen relationships with clinicians [42] Management's Comments on Operating Environment and Future Outlook - Management noted that while the dental market remains soft, there are early signals of potential improvement, such as decreasing interest rates and high unmet patient demand [47] - The company is focused on systematically improving performance and rebuilding its execution foundation [48] - Long-term outlook for the Chinese market remains positive despite current volatility [80] Other Important Information - The Spark revenue deferral change had a significant impact on Q3 results, with $27 million lower revenue due to this change [18] - The company is actively managing channel inventory, which has resulted in lower revenue but supports a healthier supply chain [20] Q&A Session Summary Question: Can you talk about whether this was a function of markets improving or just cautious execution? - Management indicated that market growth remains slow, and the performance was more about improving execution rather than market conditions [46] Question: Was there any catch-up provisions in the Spark deferral this quarter? - Management confirmed there were no changes in the deferral rate from Q2 to Q3, and the impact was primarily due to timing [65] Question: How do you think about the investments going forward? - Management stated that investments are necessary for growth and will continue into 2025, with a focus on high-return areas [76] Question: What are the areas of strength versus weakness in China? - Management expressed confidence in the long-term potential of the Chinese market, despite current geopolitical and economic volatility [80] Question: Can you provide insights on the implant organization and investments? - Management highlighted that significant investments have been made in commercial activities, which have positively impacted performance in North America [110]

Envista (NVST) reported $601 million in revenue for the quarter ended September 2024, representing a year-over-year decline of 4.8%. EPS of $0.12 for the same period compares to $0.43 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $592.28 million, representing a surprise of +1.47%. The company delivered an EPS surprise of +33.33%, with the consensus EPS estimate being $0.09.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Stre ...